Tomoyuki Kanda

1.6k total citations
34 papers, 1.3k citations indexed

About

Tomoyuki Kanda is a scholar working on Physiology, Cellular and Molecular Neuroscience and Molecular Biology. According to data from OpenAlex, Tomoyuki Kanda has authored 34 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Physiology, 15 papers in Cellular and Molecular Neuroscience and 13 papers in Molecular Biology. Recurrent topics in Tomoyuki Kanda's work include Adenosine and Purinergic Signaling (21 papers), Neuroscience and Neuropharmacology Research (9 papers) and Parkinson's Disease Mechanisms and Treatments (7 papers). Tomoyuki Kanda is often cited by papers focused on Adenosine and Purinergic Signaling (21 papers), Neuroscience and Neuropharmacology Research (9 papers) and Parkinson's Disease Mechanisms and Treatments (7 papers). Tomoyuki Kanda collaborates with scholars based in Japan, United Kingdom and Ireland. Tomoyuki Kanda's co-authors include Peter Jenner, Minoru Kobayashi, Yoshihisa Kuwana, Akihisa Mori, Koji Yamada, Joji Nakamura, Hiroshi Kase, R. K. B. Pearce, Michael Jackson and Lance A. Smith and has published in prestigious journals such as PLoS ONE, Annals of Neurology and Brain Research.

In The Last Decade

Tomoyuki Kanda

33 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tomoyuki Kanda Japan 20 610 472 419 405 148 34 1.3k
Rosaria Reggio Italy 20 618 1.0× 762 1.6× 457 1.1× 247 0.6× 61 0.4× 32 1.2k
Joji Nakamura Japan 19 880 1.4× 788 1.7× 577 1.4× 614 1.5× 138 0.9× 45 1.8k
Antonella Pèzzola Italy 25 648 1.1× 1.1k 2.4× 641 1.5× 473 1.2× 109 0.7× 64 1.8k
Yuehang Xu United States 13 561 0.9× 472 1.0× 500 1.2× 598 1.5× 38 0.3× 18 1.6k
Maria José Diógenes Portugal 22 524 0.9× 913 1.9× 461 1.1× 286 0.7× 81 0.5× 50 1.8k
Henrique B. Silva Portugal 18 437 0.7× 436 0.9× 278 0.7× 127 0.3× 92 0.6× 37 1.1k
Francisco Q. Gonçalves Portugal 18 533 0.9× 466 1.0× 286 0.7× 155 0.4× 108 0.7× 30 1.2k
Marzena Karcz‐Kubicha United States 14 430 0.7× 649 1.4× 404 1.0× 118 0.3× 55 0.4× 18 1.1k
Ágatha Oliveira‐Giacomelli Brazil 22 364 0.6× 268 0.6× 342 0.8× 133 0.3× 152 1.0× 34 1.3k
Jadwiga Wardas Poland 29 603 1.0× 1.5k 3.1× 776 1.9× 922 2.3× 103 0.7× 81 2.4k

Countries citing papers authored by Tomoyuki Kanda

Since Specialization
Citations

This map shows the geographic impact of Tomoyuki Kanda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tomoyuki Kanda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tomoyuki Kanda more than expected).

Fields of papers citing papers by Tomoyuki Kanda

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tomoyuki Kanda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tomoyuki Kanda. The network helps show where Tomoyuki Kanda may publish in the future.

Co-authorship network of co-authors of Tomoyuki Kanda

This figure shows the co-authorship network connecting the top 25 collaborators of Tomoyuki Kanda. A scholar is included among the top collaborators of Tomoyuki Kanda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tomoyuki Kanda. Tomoyuki Kanda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Fukuda, Naoko, et al.. (2023). Anti-parkinsonian activity of the adenosine A2A receptor antagonist/inverse agonist KW-6356 as monotherapy in MPTP-treated common marmosets. European Journal of Pharmacology. 950. 175773–175773. 3 indexed citations
2.
3.
Hattori, Nobutaka, et al.. (2023). Real-world evidence on levodopa dose escalation in patients with Parkinson’s disease treated with istradefylline. PLoS ONE. 18(12). e0269969–e0269969. 4 indexed citations
4.
Suzuki, Michihiko, Hidetsugu Asada, Tomoyuki Kanda, et al.. (2023). In Vitro Pharmacological Profile of KW-6356, a Novel Adenosine A2A Receptor Antagonist/Inverse Agonist. Molecular Pharmacology. 103(6). 311–324. 9 indexed citations
5.
Jenner, Peter, Akihisa Mori, & Tomoyuki Kanda. (2020). Can adenosine A2A receptor antagonists be used to treat cognitive impairment, depression or excessive sleepiness in Parkinson's disease?. Parkinsonism & Related Disorders. 80. S28–S36. 26 indexed citations
6.
Kanda, Tomoyuki & Peter Jenner. (2020). Can adenosine A2A receptor antagonists modify motor behavior and dyskinesia in experimental models of Parkinson's disease?. Parkinsonism & Related Disorders. 80. S21–S27. 18 indexed citations
7.
8.
Uchida, Shinichi, et al.. (2014). Effects of the Adenosine A2A Receptor Antagonist on Cognitive Dysfunction in Parkinson's Disease. International review of neurobiology. 119. 169–189. 19 indexed citations
9.
Kanda, Tomoyuki & Shinichi Uchida. (2014). Clinical/Pharmacological Aspect of Adenosine A2A Receptor Antagonist for Dyskinesia. International review of neurobiology. 119. 127–150. 14 indexed citations
10.
Uchida, Shinichi, et al.. (2014). The Adenosine A2A-Receptor Antagonist Istradefylline Enhances the Motor Response of L-DOPA Without Worsening Dyskinesia in MPTP-Treated Common Marmosets. Journal of Pharmacological Sciences. 124(4). 480–485. 32 indexed citations
11.
Yamada, Kôji, Minoru Kobayashi, Shizuo Shiozaki, et al.. (2014). Antidepressant activity of the adenosine A2A receptor antagonist, istradefylline (KW-6002) on learned helplessness in rats. Psychopharmacology. 231(14). 2839–2849. 50 indexed citations
12.
Kobayashi, Minoru, et al.. (2013). Effects of the adenosine A2A antagonist istradefylline on cognitive performance in rats with a 6-OHDA lesion in prefrontal cortex. Psychopharmacology. 230(3). 345–352. 57 indexed citations
13.
Yamada, Koji, et al.. (2013). In vitro pharmacological profile of the A2A receptor antagonist istradefylline. Naunyn-Schmiedeberg s Archives of Pharmacology. 386(11). 963–972. 39 indexed citations
14.
Yamada, Kôji, Makoto Takayama, Shusuke Takahashi, et al.. (2011). Effect of a centrally active angiotensin converting enzyme inhibitor, perindopril, on cognitive performance in chronic cerebral hypo-perfusion rats. Brain Research. 1421. 110–120. 49 indexed citations
15.
Furuse, Tamio, Kotaro Hattori, Ikuko Yamada, et al.. (2010). Phenotypic characterization of a new Grin1 mutant mouse generated by ENU mutagenesis. European Journal of Neuroscience. 31(7). 1281–1291. 26 indexed citations
16.
Yamada, Koji, Shinichi Uchida, Makoto Takayama, et al.. (2010). Effect of a centrally active angiotensin-converting enzyme inhibitor, perindopril, on cognitive performance in a mouse model of Alzheimer's disease. Brain Research. 1352. 176–186. 78 indexed citations
17.
Kanda, Tomoyuki, et al.. (1998). Adenosine A2A receptors modify motor function in MPTP-treated common marmosets. Neuroreport. 9(12). 2857–2860. 84 indexed citations
18.
Kanda, Tomoyuki, Michael Jackson, Lance A. Smith, et al.. (1998). Adenosine A2A Antagonist: A novel antiparkinsonian agent that does not provoke dyskinesia in Parkinsonian monkeys. Annals of Neurology. 43(4). 507–513. 279 indexed citations
19.
Nakamura, Joji, Tomoyuki Kanda, Akio Ishii, et al.. (1994). Inhibition by topiramate of seizures in spontaneously epileptic rats and DBA/2 mice. European Journal of Pharmacology. 254(1-2). 83–89. 73 indexed citations
20.
Matsuda, Toshio, Tomoyuki Kanda, Yeon Hee Seong, Akemichi Baba, & Heitaroh Iwata. (1990). p-Chlorophenylalanine attenuates the pituitary-adrenocorticol response to 5-HT1A receptor agonists in mice. European Journal of Pharmacology. 181(3). 295–297. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rosaria Reggio Breakdown of academic impact, for papers by Joji Nakamura Breakdown of academic impact, for papers by Antonella Pèzzola Breakdown of academic impact, for papers by Yuehang Xu Breakdown of academic impact, for papers by Maria José Diógenes Breakdown of academic impact, for papers by Henrique B. Silva Breakdown of academic impact, for papers by Francisco Q. Gonçalves Breakdown of academic impact, for papers by Marzena Karcz‐Kubicha Breakdown of academic impact, for papers by Ágatha Oliveira‐Giacomelli Breakdown of academic impact, for papers by Jadwiga Wardas
Rankless by CCL
2026